BD (Becton, Dickinson and Company) has entered a strategic research collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania.
The goal is clear: push the boundaries of deep human immune profiling and accelerate immune-mediated therapy development.
This partnership brings together cutting-edge technology and academic expertise to decode how the human immune system behaves at a single-cell level.
At the core of the collaboration is the development of a high-parameter flow cytometry panel. This panel is designed to capture critical immune pathways directly from whole blood.
Key capabilities include:
The new panel will support a large-scale 1,000-patient immune profiling study. The study is being conducted with the Penn Colton Center for Autoimmunity.
Important details:
This scale of profiling was once considered impractical. That has changed.
The collaboration will leverage BD’s advanced single-cell ecosystem, including:
BD teams will manage instrumentation, reagents, and spectral algorithms. I3H will lead scientific direction and clinical interpretation.
According to Dr. E. John Wherry of the University of Pennsylvania, this project highlights the power of industry–academic collaboration. The aim is to extract deeper, more actionable insights from immune cells.
High-parameter single-cell studies are now becoming essential, not experimental. They enable precision medicine approaches that were previously out of reach.
The collaboration reflects a common objective:.
translate complex immune data into meaningful clinical insights.
BD’s latest platforms, including the BD Horizon Chroma solution, are helping make high-parameter studies more accessible and scalable.
As BD Biosciences president Steve Conly noted, these tools provide the missing link between discovery science and real-world clinical application.
BD continues to position itself at the intersection of:
By partnering with institutions like I3H, BD is helping transform immune profiling from a research challenge into a clinical advantage.
This collaboration could reshape how immune-mediated diseases are studied, diagnosed, and treated worldwide.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!